The Human Neurokinin A (substance K) Receptor. Molecular Cloning of the Gene, Chromosome Localization, and Isolation of CDNA from Tracheal and Gastric Tissues
Overview
Authors
Affiliations
Neurokinin A (substance K) is a peptide neurotransmitter of the tachykinin family with potential as a major mediator in human airway and gastrointestinal tissues. Neurokinin A acts via a receptor (the NK-2 receptor) believed to be localized on smooth muscle cells and pharmacologically coupled to a GTP-binding protein. To characterize the human NK-2 receptor, we prepared a partial cDNA from human tracheal RNA using the polymerase chain reaction with oligonucleotide primers derived from the bovine NK-2 receptor cDNA sequence (Masu, Y., Nakayama, K., Tamaki, H., Harada, Y., Kuno, M., Nakanishi, S. (1987) Nature 329, 836-838). This partial human NK-2 receptor cDNA was used to screen a human genomic DNA library and yielded a clone, NGNK-2, of approximately 25 kilobases. Analysis of NGNK-2 indicates that it contains the entire coding sequence of the NK-2 receptor as well as 5'- and 3'-flanking sequences. The gene is organized with five exons interrupted by four introns. The complete sequence of the exons and the intron-exon junctions was determined, as were the transcription initiation site and the 3'-polyadenylation signal. Analysis of EcoRI digests of genomic DNA from human-mouse cell hybrids indicates a single gene for the human NK-2 receptor localized to chromosome 10. Sequence analysis of exons 1 and 5, where major differences occur between the human and animal species, provided information for polymerase chain reaction primers which allowed us to prepare full-length cDNA for the human NK-2 receptor. The protein predicted from the gene sequence is extended by 14 amino acids at the COOH terminus compared to the bovine and 9 residues compared to the rat molecules. The seven membrane-spanning regions are encoded by exons 1-4 and none is interrupted by introns. These regions are highly conserved among the species studied, suggesting stringent evolutionary control over these molecules.
Serban R, Boldeanu M, Florescu D, Ionescu M, Serbanescu M, Boldeanu L J Clin Med. 2024; 13(18).
PMID: 39337103 PMC: 11432560. DOI: 10.3390/jcm13185616.
Review of human genetic and clinical studies directly relevant to GnRH signalling.
Seminara S, Topaloglu A J Neuroendocrinol. 2021; 34(5):e13080.
PMID: 34970798 PMC: 9299506. DOI: 10.1111/jne.13080.
General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation.
Yam M, Loh Y, Tan C, Adam S, Abdul Manan N, Basir R Int J Mol Sci. 2018; 19(8).
PMID: 30042373 PMC: 6121522. DOI: 10.3390/ijms19082164.
TACR3 mutations disrupt NK3R function through distinct mechanisms in GnRH-deficient patients.
Noel S, Abreu A, Xu S, Muyide T, Gianetti E, Tusset C FASEB J. 2013; 28(4):1924-37.
PMID: 24376026 PMC: 3963009. DOI: 10.1096/fj.13-240630.
Azma T, Sugimoto Y, Kinoshita H, Ito T, Tsukamoto M, Hoshijima H J Thromb Thrombolysis. 2011; 33(4):329-37.
PMID: 22057425 DOI: 10.1007/s11239-011-0650-1.